Precision Neuroscience Accelerates Minimally Invasive BCI Rollout Following Major Clinical and Industry Milestones

In the escalating race to connect the human brain to digital devices, a New York-based startup is quietly pulling ahead by taking a gentler approach. Precision Neuroscience, founded by a former Neuralink co-founder, has hit a series of major commercial and clinical milestones in June 2026 for its Layer 7 Cortical Interface.[1][6]

This week, the company was named a winner in Fast Company's 2026 World Changing Ideas awards and secured a Webby Award for its potential to restore communication for people living with severe paralysis. These accolades arrive just as the startup strengthens its executive leadership and scales its operations following a landmark FDA 510(k) clearance.[1][2][3]

Unlike traditional brain-computer interfaces that require drilling into the skull and penetrating brain tissue with rigid electrodes, Precision's Layer 7 device is a flexible, ultra-thin film. Measuring just one-fifth the thickness of a human hair, the array contains 1,024 microelectrodes and is designed to rest gently on the surface of the cerebral cortex.[3][6]

The device can be slipped onto the brain's motor cortex through a micro-slit incision less than one millimeter wide. This minimally invasive technique avoids the scarring, inflammation, and tissue damage associated with penetrating implants, making the technology significantly safer and more accessible for vulnerable patients.[1][6]

To accelerate the technology's real-world impact, Precision launched a major clinical partnership this month with the University of Chicago Medicine. The collaboration focuses on AI-driven sensorimotor function and neuroprosthetics, allowing researchers to continuously capture high-resolution neural data for up to 30 days.[4]

By leveraging advanced artificial intelligence models, the system translates the brain's electrical signals into digital code. For a patient who has lost the ability to speak or move their hands, this decoded neural data can be used to operate a computer, control a smartphone, or even manipulate a bionic limb using only their thoughts.[2][4][6]

The startup's momentum is also being fueled by strategic industry alliances. Precision recently partnered with medical device giant Medtronic to integrate the Layer 7 interface with Medtronic's StealthStation surgical navigation system. This co-development agreement aims to give neurosurgeons real-time functional and structural information, shortening the path to widespread clinical adoption.[5]

The brain-computer interface sector is rapidly maturing from a sci-fi concept into a highly competitive medical technology market, estimated to reach 400 billion dollars in the coming decades. While competitors like Neuralink have captured much of the public's attention with robotic surgical implants, and Synchron has pioneered an endovascular approach through blood vessels, Precision is carving out a unique middle ground.[6]

With over 90 patients already implanted across multiple health systems during temporary surgical procedures, Precision is now preparing for fully implanted, chronic clinical trials. The company's ability to safely gather massive amounts of human neural data is helping to build the foundational AI models required for next-generation neuroprosthetics.[2][6]

As the startup transitions from venture-backed research to commercial medical deployment, its success signals a broader shift in the tech ecosystem. The most celebrated breakthroughs are increasingly those that solve profound human challenges with precision, proving that the future of medical hardware can be both immensely powerful and fundamentally humane.[1][2]